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Penicillin binding protein 3 
of Staphylococcus aureus NCTC 8325-4  
binds and activates human plasminogen
Riikka Kylväjä1,2, Tuomas Ojalehto1,3, Veera Kainulainen1,4, Ritva Virkola1 and Benita Westerlund‑Wikström1* 
Abstract 
Background: Staphylococcus aureus is a versatile pathogen expressing a number of virulence‑associated adhesive 
molecules. In a previous study, we generated in a secretion‑competent Escherichia coli strain a library of random 
FLAG‑tag positive (FTP) polypeptides of S. aureus. To identify adhesive proteins and gain additional knowledge on 
putative virulence factors of S. aureus, we here screened the FTP library against human serum proteins.
Findings: Staphylococcus aureus NCTC 8325‑4, origin of the FTP library, adhered to immobilized plasminogen in vitro. 
In an enzyme‑linked immunoassay a C‑terminal part of penicillin binding protein 3 (PBP3), included in the FTP library, 
bound to immobilized plasminogen. We expressed and purified full‑length PBP3 and its C‑terminal fragments as 
recombinant proteins. In a time‑resolved fluorometry—based assay the PBP3 polypeptides bound to immobilized 
plasminogen. The polypeptides enhanced formation of plasmin from plasminogen as analyzed by cleavage of a chro‑
mogenic plasmin substrate.
Conclusions: The present findings, although preliminary, demonstrate reliably that S. aureus NCTC 8325‑4 adheres 
to immobilized plasminogen in vitro and that the adhesion may be mediated by a C‑terminal fragment of the PBP3 
protein. The full length PBP3 and the penicillin binding C‑terminal domain of PBP3 expressed as recombinant proteins 
bound plasminogen and activated plasminogen to plasmin. These phenomena were inhibited by the lysine analogue 
ε‑aminocaproic acid suggesting that the binding is mediated by lysine residues. A detailed molecular description 
of surface molecules enhancing the virulence of S. aureus will aid in understanding of its pathogenicity and help in 
design of antibacterial drugs in the future.
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Findings
Research background
The human plasminogen (Plg)/plasmin system is a key 
player in the tightly controlled blood fibrinolytic pathway 
that results in dissolving small, developing blood clots 
by rapid, non-specific, proteolytic events [1, 2]. Plg cir-
culates in blood as a proenzyme in two inactive forms: 
Glu-Plg and Lys-Plg, which are activated to the serine 
protease plasmin by two physiological Plg activators, tis-
sue-type Plg activator (tPA) and urokinase Plg activator 
(uPA) [3–5]. The conversion of free Plg to plasmin by 
soluble activators in plasma is inefficient and fibrinolysis 
is generally initiated as the fibrin network in blood clots 
binds Plg that is then converted by tPA into active plas-
min [2]. uPA binds to uPA receptors on target cells where 
it activates plasminogen and the event leads to degrada-
tion of extracellular matrix and regulation of cell migra-
tion, adhesion and proliferation [5, 6].
Many bacterial species can take advantage of the host’s 
fibrinolytic system when they disseminate within the 
host and several bacterial species are known for their 
ability to generate a proteolytic surface from the human 
Plg/plasmin system. This enables bacteria to break out 
from blood clots and e.g. degrade components of the 
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extracellular matrix, complement system or tissues of 
the host [7–10]. These bacterial species express bacterial 
Plg activators and Plg receptors by which soluble Plg is 
immobilized onto the bacterial cell surface. Examples of 
bacterial Plg activators and receptors are the Pla protein 
of Yersinia pestis, streptokinase of streptococci as well as 
glyceraldehyde 3-phosphate dehydrogenase and enolase 
of Lactobacillus and streptococci [11–17].
Staphylococcus aureus colonizes the human nasophar-
ynx often without adverse effects [18, 19]. However, this 
opportunistic pathogen is also the infectious agent in e.g. 
boils and furuncles and in more severe diseases such as 
bacteremia or endocarditis [20]. For preventive measures 
and treatment of S. aureus infections, it is important to 
identify the molecular mechanisms underlying coloniza-
tion and state of infection in human beings. Similarly to 
some other pathogenic bacteria, S. aureus can generate a 
proteolytic surface that assists in invasive infections and 
has been shown to express the Plg activator staphyloki-
nase as well as various receptors for Plg on its surface [13, 
21, 22]. In this report, our aim was to analyze by an alter-
native approach, whether there are unknown proteins of 
S. aureus that bind and activate Plg and thereby increase 
its arsenal of virulence factors.
Methods
Bacterial strains and growth conditions
The  Escherichia coli -based library secreting random-
length FLAG-tag positive (FTP) polypeptides of S. aureus 
as well as the nucleotide sequences of each S. aureus gene 
fragment in the library were available from previous work 
in our laboratory [23]. Briefly, the library consists of ran-
domly fragmented chromosomal DNA of S. aureus subsp. 
aureus NCTC 8325-4 (from now on S. aureus NCTC 
8325-4). The fragments are mainly 250–1000 bp in length, 
distributed randomly and evenly on the S. aureus NCTC 
8325-4 chromosome. The library was generated in our 
expression vector, which facilitates secretion of foreign 
FLAG-tagged polypeptides into the growth medium of E. 
coli MKS12 [23]. The library, which covers approximately 
32  % of the staphylococcal proteome, includes 1663 
clones that cover 950 individual gene sequences express-
ing FTP polypeptides of S. aureus secreted into the E. 
coli MKS12 growth medium. Most of the sequences did 
not contain a known secretion signal. The folding state 
of the FTP polypeptides in the growth medium has not 
been analyzed. The clones of the E. coli MKS12 library 
were cultured in 300 μl Luria-Bertani broth (LB) supplied 
with ampicillin (150 μg/ml) on 96-well polystyrene plates 
statically overnight at 37 °C or statically in 3 ml N-mini-
mal medium as described by Majander et  al. [24]. Prior 
to protein analysis, the growth medium was clarified by 
centrifugation twice as described by Kylväjä et  al. [23]. 
Enterococcus faecium ATCC 19434, Lactobacillus crispa-
tus ST1 and S. aureus NCTC 8325-4 were available from 
previous work [23, 25] (Ritva Virkola personal commu-
nications). E. coli BL21 (AI) ΔslyD (F–ompT gal dcm lon 
hsdSB(rB- mB-) araB::T7RNAP-tetA ΔslyD::cat) origi-
nally provided by Michael S. Donnenberg (University of 
Maryland) was available from previous work [26, 27]. E. 
coli BL21 (DE3) was from Novagen. E. faecium ATCC 
19434 and S. aureus NCTC 8325-4 were grown shaking 
in 10 ml Todd-Hewitt broth (Difco; BD Biosciences) for 
18 h at 37 °C. L. crispatus ST1 was cultured statically in 
10 ml de Man, Rogosa and Sharpe broth (MRS; Difco) for 
18 h at 37 °C. E. coli BL21 (AI) ΔslyD (pREP4) and BL21 
(DE3) were grown in LB broth or on LB agar plates over-
night at 37  °C with appropriate antibiotics. The repres-
sor plasmid pREP4 was used for repression of expression 
from the pQE-type of vectors (Qiagen). To purify the His-
PBP3 recombinant proteins, the hosts 1) E. coli BL21 (AI) 
(pREP4) ΔslyD harboring the expression plasmid pQE30/
PBP3-F, and 2) BL21 (DE3) (pREP4) harboring pET45b/
PBP3-C and pET45b/PBP3-CS634 were grown shak-
ing overnight at 37  °C in LB broth with antibiotics (Km 
25  µg/ml and Amp 150  µg/ml) and diluted 1/20 in LB 
broth without ampicillin, to avoid binding of ampicillin 
to the expressed PBP3 derivatives. Then, (1) E. coli BL21 
(AI) ΔslyD (pQE30/PBP3-F) was grown for 2 h at 37  °C 
and induced with 1 mM IPTG for 2 h at 4 °C, whereas (2) 
BL21 (DE3) (pET45b/PBP3-C) and BL21 (DE3) (pET45b/
PBP3-CS634) were grown for 6  h at 37  °C before induc-
tion with 2 mM IPTG for 1 h at 37 °C. The cells used in 
recombinant protein expression were washed once with 
PBS, pelleted and stored at −20 °C.
Adhesion of bacterial cells to immobilized Plg
Human Glu-plasminogen (Glu-Plg; American Diagnos-
tica) and bovine serum albumin (BSA; Sigma-Aldrich) 
were immobilized on Diagnostic StarFrost slides (Wal-
demar Knittel, Braunschweig) by applying 40 µl Glu-Plg 
(20 µg/ml) and 40 µl BSA (25 µg/ml) in phosphate-buff-
ered saline, pH 7.1 (PBS) onto the slides. The slides were 
incubated in a moist chamber for 18 h at 20 °C, washed 
slowly shaking for 3 min in 0.1 % BSA/PBS and blocked 
statically in 2  % BSA/PBS for 2  h at 20  °C. After wash-
ing the slides slowly shaking 3  ×  5  min in 0.1  % BSA/
PBS, 40 µl of bacterial suspensions (5 × 108 bacteria/ml 
of PBS) were applied onto the slides, which were then 
incubated statically in a moist chamber for 2 h at 20 °C. 
The slides were washed slowly shaking 3  ×  3  min in 
0.1 % BSA/PBS and left to dry for 18 h at 20 °C. Adhered 
bacteria were visualized by staining of the slides with 
0.2  % Loeffler methylene blue (Merck) for 3  min. The 
slides were washed in tap water, left to dry at 20 °C and 
the number of adhered bacteria in 20 randomly chosen 
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microscopic fields (of 3.4 × 104 µm2) was quantified for 
each bacterial strain and each target protein using Image-
Pro Plus, version 4.0 TM (Media Cybernetics, Inc., USA) 
and ImageJ 1.47 software (National Institutes of Health, 
USA) for analysis of bacterial adhesion. The experiment 
was repeated three times and the result of one repre-
sentative experiment was used for calculation of average 
number of adhered bacteria and the standard deviation 
in 20 randomly chosen microscopic fields.
Primary screening of the binding of FTP polypeptides 
to immobilized Plg
Cleared supernatants of the FTP clones were prepared 
as described by Kylväjä et  al. [23] and 100  μl of each 
cleared supernatant was analyzed for binding to immo-
bilized Glu-Plg (100 nM) in an enzyme-linked immuno-
assay (ELISA). Bound FTP peptides were detected with 
anti-FLAG® M2 monoclonal antibody (0.5 μg/ml in 1 % 
BSA/PBS; Sigma-Aldrich, RRID:AB_439685) and alka-
line phosphatase-conjugated anti-mouse antibody (1 μg/
ml in 1 % BSA/PBS), and the absorbance was measured 
in a Multiscan Titertek recorder (Eflab) at 405  nm as 
described for other target proteins in Kylväjä et al. [23]. 
Clarified, cell-free supernatant of MKS12 (pSRP18/0), 
carrying an empty vector and the clone named ΔArcB, 
encoding a C-terminal fragment of the ArcB subunit of 
a multidrug efflux pump (locus tag SAOUHSC 02525), as 
well as His-tagged enolase of L. crispatus ST1 (ST1 Eno) 
were available from previous work [12, 23] and were used 
as controls.
Construction and purification of His‑tagged PBP3 proteins
We constructed the following N-terminally His-tagged 
PBP3 recombinant proteins: (a) PBP3-CS634, which 
started at the beginning of the transpeptidase domain at 
residue E327 and was truncated at the C-terminus iden-
tically to that of the FTP library polypeptide, (b) a full-
length PBP3 polypeptide named PBP3-F, which started 
from residue D58 and thereby lacked the membrane 
anchor domain, and (c) the PBP3 C-terminal domain 
named PBP3-C, which started from residue E327 and 
covered the penicillin binding transpeptidase domain [28, 
29]. To construct the described recombinant proteins, the 
pbpC gene fragment encoding PBP3-F was cloned into 
the SphI/PstI restriction site of pQE30 (Qiagen) and the 
gene fragments encoding PBP3-C and PBP3-CS634 carry-
ing two additional N-terminal His-residues, to enhance 
the binding to the affinity matrix used for protein puri-
fication, were cloned into the PmlI/BlpI restriction site 
in pET45b (Novagen). Primers used were designed on 
the basis of the pbpC sequence of S. aureus NCTC 8325 
(locus SAOUHSC_01652) as follows: forward of PBP3-F: 
5′CCCGCATGCGATGAAAACATTACAGTGAATGAG 
TCTG; reverse of PBP3-F: 5′GGGCTGCAGTTATTTG 
TCTTTGTCTTTATTTTTATCATC; forward of PBP3-C 
and PBP3-CS634: 5′CACCACGAAGTAGAAGCATTATT 
AGATAAACAAATTAAG; reverse of PBP3-C: 5′GGGC 
TCAGCTTATTTGTCTTTGTCTTTATTTTTATCATC; 
reverse of PBP3-CS634: 5′GGGGCTCAGCTTAAGAGT-
TAACTCTTGGCTCTC. Plasmid pQE30/PBP3-F was 
transformed into E. coli BL21 (AI)  (pREP4) ΔslyD to 
decrease the contamination of the endogenous SlyD pro-
tein of E. coli in the affinity purification, and plasmids 
pET45b/PBP3-C and pET45b/PBP3-CS634 into E. coli 
BL21 (DE3) for expression of proteins.
Cells expressing the N-terminally His-tagged PBP3-
F were lysed with BugBuster® Master Mix (10  ml Bug-
Buster/cells pelleted from 100  ml culture) (Novagen). 
Protein present in the soluble cell fraction was purified 
using nickel-nitrilotriacetic acid (Ni–NTA) metal-affinity 
chromatography matrix under native conditions accord-
ing to QIAexpress System (Qiagen) with the following 
minor modifications. All buffers were supplemented with 
10  % glycerol to stabilize the recombinant proteins. In 
addition, the lysis buffer was supplemented with 15 mM 
imidazole and the wash buffer with 40  mM imidazole. 
Cells expressing the N-terminally His-tagged PBP3-C 
and PBP3-CS634 were lysed with QIAexpress native lysis 
buffer (5 ml/g cells), where after PBP3-CS634 and PBP3-C 
in the non-soluble fractions were solubilized with QIA-
express Urea lysis buffer (10  ml/g pellet). The proteins 
were purified under denaturing conditions using Ni-NTA 
agarose according to manufacturer’s instructions. After 
purification under denaturing conditions, the PBP3-C 
and PBP3-CS634 proteins were refolded by changing the 
urea-containing elution buffer to PBS containing 10  % 
glycerol in a PD-10 gel filtration column (GE Healthcare). 
The purification process was monitored by SDS-PAGE 
analysis and the concentration of the purified proteins 
was determined by analyzing the whole band intensity 
from Coomassie-stained SDS-PAGE gels, with BSA as a 
standard of known concentrations and using the TINA 
2.09c software (Rayest Isotopen Meβgeräte). The second-
ary structure of the proteins was not assessed.
Binding of purified His‑tagged PBPs to soluble Plg
The binding of purified His-tagged PBP3 proteins to 
soluble Plg was analyzed by time-resolved fluorometry 
developed by Hurmalainen et al. [12] and Kukkonen et al. 
[30] with minor modifications. Briefly, the concentra-
tion of all proteins to be analyzed for binding to Plg was 
adjusted to 625 nM in PBS/10 % glycerol and the analysis 
was assessed at a final concentration of 100  nM in PBS 
(100 µl/well). The His-tagged PBP3 proteins, the positive 
control protein laminin (Lam; Sigma-Aldrich) [31] and 
negative control protein ΔNarG (locus tag SAOUHSC 
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02681) available from previous work [23], were immo-
bilized on polystyrene microtiter plates overnight at 
21 °C, the plates were washed and blocked with 2 % BSA/
PBS. Glu-Plg (1 µg/well) was added to the wells and the 
plate was incubated for 4 h at 21 °C. For inhibition stud-
ies, Glu-Plg in PBS/0.1 % Tween 20 was incubated with 
ε-aminocaproic acid (EACA; 10 mM) for 15 min at 21 °C 
prior to its application onto the immobilized target pro-
teins. The binding of Plg was assessed with parallel sam-
ples using polyclonal anti-human Plg IgG (720  ng/well, 
2  h, 21  °C; American Diagnostica, RRID: AB_400685) 
and Eu3+-labelled anti-rabbit IgG (80 ng/well, 18 h, 4 °C; 
PerkinElmer) and measured in a VICTOR® time-resolved 
fluorometer with DELFIA® enhancement solution 
(PerkinElmer) using filter settings 340  nm (excitation) 
and 615  nm (emission). The volume was 100  μl in each 
step except for the enhancement solution that was used 
at 250 µl. The experiment was repeated twice with very 
similar outcomes. The average and standard deviation of 
two parallel samples were calculated on the basis of the 
results of one of the experiments.
Formation of active plasmin by purified proteins
His-tagged PBP3-F, PBP3-C and PBP3-CS634 (100  nM), 
Lam (100  nM) and ΔNarG (100  nM) in PBS/10  % glyc-
erol were mixed in polystyrene microtiter wells with 
Glu-Plg (4 µg/well), and the tissue-type Plg activator tPA 
(2 ng/well; Calbiochem) in PBS. Controls included were 
(1) wells without Plg, (2) wells without tPA, (3) wells 
without Plg and tPA, and (4) wells without His-tagged 
PBP3 proteins. The lacking reaction components were 
substituted with buffer. For inhibition studies, EACA 
(0.73 mM) was added to the wells 5 min prior to Glu-Plg 
addition. The chromogenic plasmin substrate SS-2251 
(H–D-Val-Leu-Lys-p-nitroanilinehydrochloride; Kabivit-
rum) was added (0.45 mM) to all wells prior to measure-
ment of the absorbance in a Multiscan Titertek recorder 
(Eflab) at 405  nm (time point T0). Final volume in each 
well was 200 μl. The absorbance was measured at inter-
vals of 15–30 min for 4. 5 h and values of T0 were sub-
tracted from measurements of the other time points as 
well as the background level of the activation of substrate 
SS-2251 in buffer. The experiment with parallel samples 
was repeated twice; the average and standard deviation of 
two parallel samples were calculated on the basis of the 
results of one of the experiments.
Results and discussion
We have previously generated a library of random FLAG-
tag positive polypeptides (FTP library) of strain S. aureus 
NCTC 8325-4 in the secretion-competent E. coliK12 
derivative called MKS12. This strain can secrete heter-
ologous proteins into the growth medium [23, 24] and 
the heterologous polypeptides can be analyzed directly in 
the growth medium of E. coli MKS12 for binding to vari-
ous target molecules as described by Majander et al. [24] 
and Kylväjä et al. [23]. In this report, we first analyzed the 
adhesion of S. aureus NCTC 8325-4 cells to Plg and then 
assessed the binding to Plg in  vitro by S. aureus NCTC 
8325-4 polypeptides present in the E. coli MKS12—based 
FTP library.
Adhesion of E. faecium ATCC 19434, L. crispatus ST1 
and S. aureus NCTC 8325-4 to immobilized Plg and 
BSA was assessed. We chose the strain S. aureus NCTC 
8325-4 for the adhesion assay, since its chromosome had 
been used when we constructed the FTP library [23], 
which also was used for screening purposes in this report. 
To our knowledge, binding of Plg has been demonstrated 
with other S. aureus strains [21, 22, 32], but never with 
the commonly used laboratory strain S. aureus NCTC 
8325-4. L. crispatus ST1 has previously been proven to 
bind and activate Plg and it was used here as a positive 
control [12, 13]. E. faecium has not been demonstrated 
to interact with Plg and was therefore applied as a puta-
tive negative control strain here. In the in vitro adhesion 
assay, S. aureus adhered efficiently to Plg (ca 4830 bac-
teria per microscopic field), but not to BSA (Fig. 1). The 
adhesive capacity of L. crispatus to Plg was much lower 
(ca 2580 bacteria per microscopic field), whereas E. fae-
cium did not significantly adhere to Plg or BSA (primary 
data is shown in Additional file 1).
Staphylococcus aureus is known to express the single 
plasminogen activator staphylokinase and a few plas-
minogen receptors, such as Sbi, Ebh and α-enolase, on 
its surface [13, 22, 32, 33]. We next wanted to examine 
Fig. 1 Binding of bacterial cells to immobilized Plg. Glu‑Plg (20 μg/
ml) and BSA (25 μg/ml) were immobilized onto diagnostic glass 
slides. Enterococcus faecium ATCC 19434, Lactobacillus crispatus ST1 
and Staphylococcus aureus NCTC 8325‑4 (5 × 108 cells/ml) were 
allowed to adhere to the immobilized proteins. Adhered bacteria 
were visualized by staining with Loeffler’s methylene blue. The 
number of adhered bacteria was quantified microscopically. The 
mean and the ± SD of adhered bacteria in 19 or 20 randomly chosen 
microscopic fields in a representative experiment are shown
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whether S. aureus NCTC 8325-4 expresses putative Plg 
receptors in addition to the well-known ones. To explore 
that, we screened the polypeptides of the FTP library 
for their binding to Plg (Fig.  2a, primary data is shown 
in Additional file  2). One specific library clone, named 
ΔPBP3, attracted our attention. The extracellular poly-
peptide secreted by the ΔPBP3 clone bound to Plg in 
an ELISA assay much more efficiently than peptides 
secreted by any other clone of the FTP library (Fig. 2a). 
We next confirmed the result obtained from the screen-
ing experiment with the Plg-binding clone ΔPBP3 
(Fig. 2b). The clarified growth medium from the ΔPBP3 
library clone bound to immobilized plasminogen as well 
as the enolase of L. crispatus ST1 (ST1 Eno), reported to 
bind plasminogen [12, 13]. The clarified growth medium 
of the clone named ΔArcB or the host strain MKS12 
(pSRP18/0) used as negative controls did not bind to 
immobilized Plg (Fig. 2b, primary data is shown in Addi-
tional file 2). Based on the sequence of the S. aureus gene 
carried by clone ΔPBP3, the gene product and thereby 
the polypeptide secreted into the E. coli growth medium 
is a C-terminal fragment of penicillin binding protein 3 
(PBP3; locus tag SAOUHSC 02430) (Fig. 3) [23]. 
Penicillin binding proteins (PBPs) are involved in the 
last steps of peptidoglycan biosynthesis in bacteria [34]. 
The penicillin binding domains of PBPs are targets of 
β-lactam antibiotics including penicillin, hence the name 
[28, 35]. The β-lactam antibiotics mimic the PBP sub-
strate and bind irreversibly to a conserved serine residue 
in the active groove of the enzyme, thereby inhibiting its 
activity [36, 37]. PBPs are multimodular proteins that are 
classified into high-molecular-weight (HMW) and low-
molecular-weight (LMW) PBPs. HMW PBPs are fur-
ther classified as class A or class B PBPs and the LMW 
PBPs that function as carboxypeptidases are also referred 
to as class C PBSs [35]. The HMW PBPs of class A are 
bifunctional enzymes containing (1) a non-penicillin 
binding glycosyltransferase (GTase) domain that cata-
lyzes elongation of the glycan chain of peptidoglycan 
and (2) a C-terminal, penicillin binding transpeptidase 
(TPase) domain that crosslinks the peptidoglycan. The 
only known enzymatic function for class B HMW PBPs 
is the TPase activity of the C-terminal penicillin binding 
domain (Fig. 3). The N-terminal dimerization domain of 
class B PBPs has been postulated to act as an intramo-
lecular chaperone that assists the proper folding of the 
C-terminal domain or have a role in cell morphogenesis 
[28, 38].
PBP3 is one of the four penicillin binding proteins 
(named PBP1-PBP4) of methicillin sensitive S. aureus 
and belongs to class B HMW PBPs [39–42]. PBP3 is con-
sidered as an enzyme non-essential for growth and sur-
vival of S. aureus [42]. The specific role for PBP3 is not 
known. The cell morphology of mutant strains lacking 
the pbpC gene that encodes PBP3 do not differ signifi-
cantly from cells expressing PBP3, but the mutant cells 
exhibit increased methicillin resistance [29, 42].
To verify the Plg binding properties of PBP3 that we 
observed with the ΔPBP3 FTP polypeptide, we cloned 
and expressed an N-terminally His-tagged polypeptide 
named PBP3-CS634, which started at the beginning of the 
transpeptidase domain at residue E327, and was trun-
cated at the C-terminus identically to the FTP library 
polypeptide (Fig.  3). SDS-PAGE analysis of the purified 
PBP3-CS634 polypeptide is shown in Fig. 4a. The binding 
of PBP3-CS634 to human Glu-Plg was assessed by time-
resolved fluorometry, where the His-tagged PBP3-CS634 
protein was immobilized in polystyrene wells and soluble 
Fig. 2 Binding of cell‑free growth medium of the FTP library clones to immobilized plasminogen. a Binding of clarified growth medium from 95 
representative FTP library clones to immobilized plasminogen is shown. The clone encoding a fragment of S. aureus PBP3 is named ΔPBP3. Clarified 
growth medium of the 96th clone, the host strain MKS12 carrying the empty vector pSRP18/0, was used as the background level and the value 
obtained with this control was subtracted from the other results. The results were measured in ELISA plate reader at A405nm. b Binding of the clarified 
growth medium from the ΔPBP3 library clone to immobilized plasminogen is shown. Purified, His‑tagged enolase of Lactobacillus crispatus ST1 (ST1 
Eno) represents a positive control protein and the clarified supernatant from the clone named ΔArcB, encoding a fragment of S. aureus ArcB protein, 
represents the negative control. The binding of clarified supernatant from MKS12 (pSRP18/0), named as Control, is also shown. The results were 
measured in ELISA plate recorder at A405nm. The mean and ± SD of duplicate samples from a representative experiment are shown
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Plg was allowed to bind. This setup mimics the situation 
in  vivo, where Plg receptors are attached to the bacte-
rial surface and soluble Plg is recruited to the surface by 
the Plg receptors. Immobilization of Plg/plasmin onto 
the bacterial surface, or onto host tissues, enhances the 
plasmin formation and protects the activated plasmin 
from physiological inhibitors such as α2-antiplasmin [1, 
4]. PBP3-CS634, as well as the control protein laminin, 
bound efficiently Plg, whereas ΔNarG, which was used 
as a negative control protein, did not bind Plg (Fig.  4a, 
Primary data is shown in Additional file 3). C–terminally 
located and internal repetitive lysine residues, as well as 
other positively charged amino acid motifs, present in 
various Plg-binding proteins are known to bind to the 
kringle domains of Plg. The lysine-mediated binding can 
be inhibited by the lysine analogue EACA [43–48]. The 
binding of immobilized PBP3-CS634 to soluble Plg was 
inhibited by EACA, which indicates that lysine residues 
are involved in the binding (Fig. 4a). PBP3 contains lysine 
residues at the ultimate C-terminus (Fig.  3, SA-PBP3), 
but the ΔPBP3 FTP polypeptide and the PBP3-CS634 did 
not include the C-terminal lysine-rich sequence of PBP3 
(Fig.  3, ΔPBP3 and PBP3-CS634). The results obtained 
with truncated, recombinant PBP3-C polypeptides 
suggest that other residues than C-terminal lysine resi-
dues are important in the binding of soluble Plg to PBP3 
of S. aureus. This hypothesis is supported by the fact 
that ΔPBP3 and PBP3-CS634  contain an internal lysine-
rich region (KDEVGPLKKKINGTVLNKVNNTEKEIK) 
located 104 amino acid residues N-terminally from the 
ultimate C-terminus of PBP3 (Fig. 3). Enolase of strepto-
cocci has similarly been shown to bind and activate Plg 
via internal, surface-exposed lysine residues [49].
We next wanted to test the binding of the full length 
PBP3 and the full C-terminal transpeptidase domain of 
the PBP3 protein to soluble Plg similarly as we did with 
the PBP3-CS634 protein. The genes encoding the His-
tagged PBP3 polypeptide named PBP3-F, which started 
from residue D58 and thereby lacked the membrane 
anchor domain, and the His-tagged C-terminal domain 
named PBP3-C, which started from residue E327 and 
covered the penicillin binding transpeptidase domain of 
the protein [28, 29] (Fig. 3), were cloned and the corre-
sponding gene products were purified. SDS-PAGE anal-
ysis of purified PBP3-F and PBP3-C is shown in Fig. 4b. 
PBP3-F and PBP3-C both bound soluble Plg similarly as 
the PBP3-CS634 protein and EACA inhibited the binding 
(Fig. 4b, Primary data is shown in Additional file 3).
Anchor Transpeptidase (PB) domain
D361 S634
D58 K691
E327
M1 P68 V301 V353
SA-PBP3
K691
KGLGKDDKNKDKDK
N655
FLAGFliC
6xHis
8xHis
K691
ΔPBP3
PBP3-F
PBP3-C
E327 S634
8xHis PBP3-CS634
KDEVGPLKKKINGTVLNKVNNTEKEIK
Dimerization (n-PB) domain
Fig. 3 Schematic presentation of S. aureus PBP3 and PBP3 fragments expressed as His‑tagged recombinant proteins. The PBP3 of S. aureus (SA‑
PBP3) with a non‑penicillin binding (n‑PB) dimerization domain connected by an inter‑domain hinge to a penicillin binding (PB) transpeptidase 
domain is shown uppermost. ΔPBP3 is encoded by the FTP library clone and it carries an N‑terminal signal for secretion (FliC) and a C‑terminal 
FLAG‑tag encoded by the expression vector pSRP18/0. The recombinant protein named PBP3‑CS634 carries eight N‑terminal histidine residues and 
the truncated sequence of the penicillin binding (PB) domain of PBP3. The recombinant protein named PBP3‑C carries eight N‑terminal histidine 
residues and the sequence of the penicillin binding (PB) domain of PBP3. The recombinant protein PBP3‑F carries an N‑terminal hexahistidine tag 
(His), the non‑penicillin (n‑PB) and penicillin binding (PB) domains, but lacks the N‑terminal membrane anchor sequence (Anchor) of native PBP3. 
The N‑ and C‑terminal amino acid residues of the domains are indicated below each protein. The lysine‑rich sequences of SA‑PBP3 are indicated 
(KDEVGPLKKKINGTVLNKVNNTEKEIK and KGLGKDDKNKDKDK)
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When soluble Plg is immobilized by Plg receptors on 
the bacterial surface in vivo, it is converted to active plas-
min by the physiological activators tPA or uPA [10] or by 
bacterial activators [32]. We next assessed whether tPA 
activated the PBP3-bound, proteolytically inactive Plg 
into active plasmin. Our results, obtained by measuring 
the cleavage of a chromogenic plasmin substrate, showed 
that plasminogen was activated into plasmin in the pres-
ence of PBP3-F, PBP3-C or PBP3-CS634 and tPA (Fig. 5). 
The positive control protein laminin also enhanced tPA-
mediated activation of Plg into plasmin whereas ΔNarG 
had no effect on plasmin formation. PBP3-F, PBP3-C, 
PBP3-CS634 or laminin did not activate Plg directly into 
plasmin when tPA was not present (Fig. 5, w/o tPA), indi-
cating that PBP3 does not function as a direct Plg activa-
tor. The tPA mediated plasmin activity was not enhanced 
in the presence of EACA implying that lysine residues 
are important in the interaction of Plg and PBP3 proteins 
(Fig.  5, EACA). The binding of Plg to the putative Plg 
receptors PBP3-F, PBP3-C or PBP3-CS634 as well as the 
control protein laminin, was required for tPA mediated 
activity since Plg and tPA alone did not provoke plasmin 
activity (Fig. 5, Ctrls). Furthermore, our results show that 
PBP3-F, PBP3-C and PBP3-CS634 did not alone, when 
tPA and Plg were not present, cleave the chromogenic 
substrate although the PBP3 proteins contain an active-
site serine similarly as the serine proteases that cleave 
the chromogenic substrates (Fig. 5, w/o tPA or Plg) [29, 
50]. Primary data of Fig. 5 is shown in Additional file 4. 
Altogether these results imply that the PBP3 protein acts 
as a Plg receptor in  vitro. The enhanced plasmin activ-
ity is mediated by tPA only after the inactive, soluble Plg 
is bound by PBP3-F, PBP3-C or PBP3-CS634 via internal 
lysine residues.
The penicillin binding domain of PBP3 that synthesizes 
the last steps in S. aureus cell wall polymerization is located 
outermost from the cell membrane in PBP3, but it is cur-
rently not known whether it is exposed e.g. during the cell 
wall turnover or released to the extracellular milieu. Sur-
face exposure would enable binding of soluble Plg by this 
putative Plg receptor. The biological role of PBP3 and 
other PBPs in plasmin formation in  vivo remains still to 
be revealed. Muthukrishnan et  al. [51] have shown that 
planktonic, nasal carrier strains of S. aureus secrete PBPs 
among other molecules. Additionally, PBP2 of S. aureus 
has been shown to protrude to the extracellular environ-
ment in methicillin resistant S. aureus [52] and to be local-
ized to membrane vesicles of S. aureus ATCC 14458 [53]. 
Other types of PBPs have been found in the exoproteome 
of other bacterial species, such as Clostridium difficile, 
Streptococcus agalactiae and Corynebacterium pseudotu-
berculosis [54–56]. These findings imply that PBPs might 
have moonlighting functions [57] outside the bacterial cell 
wall. In this study, the full length His-tagged PBP3 clearly 
bound Plg in vitro and enhanced the tPA mediated activa-
tion of bound plasminogen. The binding was localized to 
the C-terminal domain of PBP3, where repetitive internal 
a
b PBP3-F
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PBP3-CS634 Lam ΔNarG
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PBP3-F         PBP3-C      Lam ΔNarG
Fig. 4 Binding of soluble plasminogen to His‑tagged recombinant 
PBP3 proteins. The binding of soluble plasminogen to immobilized 
a PBP3‑CS634 and b PBP3‑F and PBP3‑C was measured with VICTOR
® 
time‑resolved fluorometer as counts per second (cps) at 340/615 nm. 
Laminin (Lam) and ΔNarG were included as controls. The test 
included binding in the presence of the proteins to be tested and (i) 
Plg (black bars, Plg), (ii) Plg and EACA (grey bars, EACA), (iii) binding in 
the absence of Plg or EACA (white bars, w/o). The mean and the ±SD 
of duplicate samples of one representative experiment are shown. 
SDS‑PAGE analysis of the purified PBP3‑CS634, PBP3‑F and PBP3‑C 
recombinant proteins are shown above the respective fluorometry 
results in figure a and b
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lysine residues reside. These results imply the putative role 
of PBP3 as a Plg receptor on the cell surface of S. aureus. 
However, the presence and the role of PBP3, and other 
PBPs, on cell surface or in the exoproteome of S. aureus 
should be further studied.
Plg activation is a well-known virulence trait of many 
bacterial species [11] and the activation might lead to 
invasive infections. S. aureus is carried in the naso-
pharynx by 20–40  % of human population and the car-
rier status can lead to severe invasive infections [58, 59]. 
The nasal carrier strains of S. aureus have been shown to 
secrete PBPs [51, 60] and their role in invasive infections 
should be further studied. The results presented in this 
study indicate that PBPs might have a moonlighting role 
as Plg receptors in invasive infections.
Additional files
Additional file 1. Primary data of bacterial adhesion to Plg and BSA 
(Fig. 1).
Additional file 2. Primary data of plasminogen binding by FTP library 
clones (Fig. 2).
Additional file 3. Primary data of Plg binding by recombinant proteins 
(Fig. 4).
Additional file 4. Primary data of Plg activation by recombinant proteins 
(Fig. 5).
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